|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In survival analysis, a low expression of CASZ1 was significantly correlated with unfavorable progression-free survival (PFS) (<i>p</i> < 0.001), overall survival (OS) (<i>p</i> < 0.001), and cancer-specific survival (CSS) (<i>p</i> < 0.001) and was an independent prognostic factor for PFS and CSS in multivariate analysis adjusted for tumor size, WHO/ISUP grade, T category, N category, and M category.
|
31481981 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There remains a paucity of literature on survival related to pediatric appendiceal tumors.
|
29656783 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our study for the first time demonstrated that CASZ1 is a tumor suppressor in HCC, which may serve as a novel prognostic predictor and therapeutic target for HCC patients.
|
29506567 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast to nonobese diabetic severe combined immunodeficient <i>Il2rg</i><sup>-/-</sup> (NSG) mice, human NK cells in SRG-15 mice did not require preactivation but infiltrated a Burkitt's lymphoma xenograft and efficiently inhibited tumor growth following treatment with the therapeutic antibody rituximab.
|
29078283 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ECRF is associated with poorer long-term survival related to a reduced utilisation of neoadjuvant chemoradiotherapy and an increased incidence of tumour margin involvement at surgery.
|
28236769 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We identify hundreds of microRNAs whose direction and/or significance of tumor-normal differential expression is associated with one or more lifestyle, tumor molecular phenotype, or survival-related factors.
|
29084506 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, cytoplasmic-restricted CASZ1 staining or low nuclear CASZ1 staining is found in tumor samples from patients with poor prognosis.
|
27270431 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We examined patient survival related to tumor locations, surgical treatment, postoperative course, radiotherapy, chemotherapy, patient age, GBM recurrence, imaging characteristics, serum, and molecular markers.
|
23614654 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CASZ1 functions as a tumor suppressor in NB; here we sought to determine how loss of CASZ1 contributes to cell cycle dysregulation in NB.
|
23892435 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In neuroblastoma tumors, loss of CASZ1 is associated with poor prognosis and restoration of CASZ1 function suppresses neuroblastoma tumorigenicity.
|
22331471 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Of particular note is that one of the genes involved is the recently described novel tumor suppressor gene castor zinc finger 1.
|
22262398 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression.
|
21252912 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our previous study showed that full length CASZ1 (CASZ1a) functions to suppress growth in neuroblastoma tumor.
|
21490919 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CASZ1 is expressed in a number of human tumors and localizes to a chromosomal region frequently lost in tumors of neuroectodermal origin.
|
16631614 |
2006 |